At the Clinical Trial Supply West Coast 2024 conference, serial biotech entrepreneur Umar Hayat said science should be allowed to advance without political interference.
The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated ...
Investor's Business Daily on MSN3d
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient DeathsBiotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
Shares in iTeos Therapeutics dropped over 20% despite positive interim data from the GALAXIES Lung-201 Phase II study with ...
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...
Bank of America Securities analyst Jason Zemansky maintained a Hold rating on Arcus Biosciences (RCUS – Research Report) today and set a ...
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...
AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.
The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...
Teos Therapeutics' belrestotug shows promising response rates in lung cancer trials. Read more to see why I'm bullish on ITOS ...
Eva Fortea Verdejo, an analyst from Wells Fargo, maintained the Buy rating on iTeos Therapeutics (ITOS – Research Report). The associated ...
Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback